Developing therapeutics for the treatment of rare hematological and iron overload diseases
Merganser is advancing a novel peptide therapeutic that mimics the functional activity of a recently discovered peptide, hepcidin, that is the body’s central regulator of iron. Merganser’s programs are addressing a range of orphan diseases where elevated iron levels contribute to the morbidity of the disease, including beta thalassemia, polycythemia vera, and other hematological diseases.
